Mohammad H Abu Arja1, Joseph R Stanek1, Jonathan L Finlay1, Mohamed S AbdelBaki2. 1. The Division of Hematology, Oncology and Blood and Marrow Transplant, Nationwide Children's Hospital, The Ohio State University, 700 Children's Dr, Columbus, OH, 43205, USA. 2. The Division of Hematology, Oncology and Blood and Marrow Transplant, Nationwide Children's Hospital, The Ohio State University, 700 Children's Dr, Columbus, OH, 43205, USA. Mohamed.AbdelBaki@nationwidechildrens.org.
Abstract
BACKGROUND: The lack of a standard treatment approach has contributed to poor outcomes of patients with recurrent central nervous system (CNS) mixed malignant germ cell tumors (MMGCT). There are no data in the literature supporting optimal re-induction chemotherapy regimens that should be used for patients with recurrent CNS MMGCT. METHODS: We conducted a literature review to explore the response rate of patients with recurrent CNS MMGCT to different re-induction chemotherapy regimens by searching PubMed from 1985 through November 2017. Tumors were classified according to Japanese, European, and North American prognostic group classifications determined at initial presentation. RESULTS: Forty-two responses to various re-induction chemotherapy regimens reported in 38 patients were included. Two patients were inevaluable and their responses to re-induction chemotherapy were excluded. Thirty-five responses to various re-induction chemotherapy regimens were evaluable in 33 patients following a first relapse. Six (17%) responses were reported as complete or continuous complete responses, seven (20%) partial responses, two (6%) were stable disease, two (6%) were mixed responses, and 18 (51%) were progressive disease. Five of ten patients treated without platinum-based chemotherapy experienced tumor progression. There was a trend towards a higher rate of tumor progression among histological poor prognostic group patients, and among patients relapsing within 24 months of initial diagnosis; however, it was not statistically significant. CONCLUSIONS: The histological prognostic group and time to relapse may affect the response to re-induction chemotherapy. However, further studies with larger sample size are needed to examine these associations and determine the optimal re-induction chemotherapy regimens for patients with recurrent MMGCT.
BACKGROUND: The lack of a standard treatment approach has contributed to poor outcomes of patients with recurrent central nervous system (CNS) mixed malignant germ cell tumors (MMGCT). There are no data in the literature supporting optimal re-induction chemotherapy regimens that should be used for patients with recurrent CNS MMGCT. METHODS: We conducted a literature review to explore the response rate of patients with recurrent CNS MMGCT to different re-induction chemotherapy regimens by searching PubMed from 1985 through November 2017. Tumors were classified according to Japanese, European, and North American prognostic group classifications determined at initial presentation. RESULTS: Forty-two responses to various re-induction chemotherapy regimens reported in 38 patients were included. Two patients were inevaluable and their responses to re-induction chemotherapy were excluded. Thirty-five responses to various re-induction chemotherapy regimens were evaluable in 33 patients following a first relapse. Six (17%) responses were reported as complete or continuous complete responses, seven (20%) partial responses, two (6%) were stable disease, two (6%) were mixed responses, and 18 (51%) were progressive disease. Five of ten patients treated without platinum-based chemotherapy experienced tumor progression. There was a trend towards a higher rate of tumor progression among histological poor prognostic group patients, and among patients relapsing within 24 months of initial diagnosis; however, it was not statistically significant. CONCLUSIONS: The histological prognostic group and time to relapse may affect the response to re-induction chemotherapy. However, further studies with larger sample size are needed to examine these associations and determine the optimal re-induction chemotherapy regimens for patients with recurrent MMGCT.
Entities:
Keywords:
Central nervous system tumor; Germ cell tumor; Mixed malignant germ cell tumor; Non-germinomatous germ cell tumor; Re-induction chemotherapy; Relapse
Authors: Hee Jo Baek; Hyeon Jin Park; Ki Woong Sung; Soo Hyun Lee; Jung Woo Han; Kyung Nam Koh; Ho Joon Im; Hyoung Jin Kang; Kyung Duk Park Journal: J Neurooncol Date: 2013-07-04 Impact factor: 4.130
Authors: Rachel Pruitt; Nasjla S DaSilva; Andrea Cappellano; Clara Belessiotis; Blanca Diez; Sharon Gardner; Jeffrey Allen; Mark Weinblatt; Nicholas Gottardo; Girish Dhall; Jonathan L Finlay Journal: Pediatr Blood Cancer Date: 2015-06-05 Impact factor: 3.167
Authors: M C Baranzelli; C Patte; E Bouffet; M Portas; F Mechinaud-Lacroix; E Sariban; H Roche; C Kalifa Journal: J Neurooncol Date: 1998-05 Impact factor: 4.130
Authors: Shakeel Modak; Sharon Gardner; Ira J Dunkel; Casilda Balmaceda; Marc K Rosenblum; Douglas C Miller; Steven Halpern; Jonathan L Finlay Journal: J Clin Oncol Date: 2004-05-15 Impact factor: 44.544
Authors: Nasjla Saba da Silva; Andrea M Cappellano; Blanca Diez; Sergio Cavalheiro; Sharon Gardner; Jeffrey Wisoff; Stewart Kellie; Robert Parker; James Garvin; Jonathan Finlay Journal: Pediatr Blood Cancer Date: 2010-03 Impact factor: 3.167
Authors: Matthew J Murray; Shivani Bailey; Katja Heinemann; Jillian Mann; Ulrich K Göbel; Frank Saran; Juliet P Hale; Gabriele Calaminus; James C Nicholson Journal: Int J Cancer Date: 2017-05-15 Impact factor: 7.396